一个智能安全的虚拟现实沉浸式应用程序,用于阿尔茨海默氏症和痴呆症患者
Murad Al-Rajab1, Joan Lu2, Saad Amawi3
1Abu Dhabi University, Abu Dhabi, UAE. murad.al-rajab@adu.ac.ae.
Scientific reports
|August 20, 2025
概括
本研究介绍了一种结合虚拟现实 (VR),语音识别和人工智能 (AI) 的新型非侵入性系统,以支持阿尔茨海默病 (AD) 患者. 综合框架增强了认知功能和社会互动,改善了阿尔茨海默病和痴呆症患者的生活质量.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 计算机科学 计算机科学
背景情况:
- 阿尔茨海默病 (AD) 显著影响老年人,导致认知能力下降和社会孤立.
- 现有的干预措施经常使用侵入性可穿戴设备,引发隐私问题.
- 对阿尔茨海默病患者来说,需要非侵入性,引人入胜的支持系统.
研究的目的:
- 为阿尔茨海默病 (AD) 患者开发和评估一种新的非侵入性支持系统.
- 整合虚拟现实 (VR),语音识别和人工智能 (AI) 进行认知刺激和陪伴.
- 解决当前干预措施的局限性,包括隐私问题和缺乏动态适应.
主要方法:
- 开发了一个结合VR,语音识别和AI的新框架.
- 该系统通过沉浸式VR场景,记忆游戏和虚拟旅行提供量身定制的认知刺激.
- 基于人工智能的患者评估确保了个性化和相关的体验,以语音识别为主要接口.
主要成果:
- 涉及患者,家庭和临床医生的初步研究显示出有前途的结果.
- 参与者报告说,兴趣增加,生活质量改善,隔离减少,认知功能增强.
- 该系统在改善阿兹海默症患者的心理健康护理和福祉方面表现出有效性.
结论:
- 集成的VR,语音识别和AI框架代表了支持AD患者认知功能和社交互动的重大进步.
- 该系统提供了动态的认知适应,双语交互和安全的实时个性化,超越了现有的解决方案.
- 这项研究强调了这项技术在提高认知障碍的老年人生活质量和心理健康护理方面的潜力.
相关概念视频
Cognitive Development During Adulthood
267
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
267
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666


